Literature DB >> 20566393

DNA vaccine expressing HIV-1 gp120/immunoglobulin fusion protein enhances cellular immunity.

Masaru Shimada1, Shinji Yoshizaki, Nao Jounai, Asami Kondo, Motohide Ichino, Akihide Ryo, Kenji Okuda.   

Abstract

In this study, we explored the possibility of augmenting human immunodeficiency virus (HIV) gp120-specific cell-mediated immune responses in mice by means of a DNA vaccine encoding a mouse Ig Fcgamma2a fragment fused with gp120 (gp120-Ig, Ig-gp120). Western blotting analysis revealed that the HIV gp120 protein expression efficiency was higher in cells transfected with the gp120-Ig-coding plasmid (pGp120Ig) than in those transfected with the gp120 and Ig-gp120 expression plasmids (pGp120 and pIgGp120, respectively). pGp120Ig elicited more HIV-specific CD8 T cells and effector memory CD8 T cells than pGp120 in immunized mice. Furthermore, pGp120Ig significantly reduced the viral load after challenge with an HIV Env gp160-expressing vaccinia virus. These results demonstrate that covalent antigen modification with an Ig sequence can modulate antigen-specific cellular immune responses. The approach may be useful for vaccine development. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20566393     DOI: 10.1016/j.vaccine.2010.05.035

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Vaccination with Human Induced Pluripotent Stem Cells Creates an Antigen-Specific Immune Response Against HIV-1 gp160.

Authors:  Shinji Yoshizaki; Mayuko Nishi; Asami Kondo; Yoshitsugu Kojima; Naoki Yamamoto; Akihide Ryo
Journal:  Front Microbiol       Date:  2011-02-22       Impact factor: 5.640

Review 2.  New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.

Authors:  Takehiro Ura; Akio Yamashita; Nobuhisa Mizuki; Kenji Okuda; Masaru Shimada
Journal:  Vaccine       Date:  2020-11-24       Impact factor: 3.641

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.